vanflyta
daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukémia, mieloid - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.
dabigatrán-etexilát stada 75 mg kemény kapszula
stada arzneimittel ag - dabigatran etexilát mezilát -
irinotecan actavis 20 mg/ml koncentrátum oldatos infúzióhoz
teva b.v. - irinotecan -
fosicard 5 mg tabletta
actavis group hf. - fosinopril -
fosicard 10 mg tabletta
actavis group hf. - fosinopril -
fosicard 20 mg tabletta
actavis group hf. - fosinopril -
sedaton 25 mikrogramm/h transzdermális tapasz
actavis group hf. - fentanil -
sedaton 50 mikrogramm/h transzdermális tapasz
actavis group hf. - fentanil -
sedaton 75 mikrogramm/h transzdermális tapasz
actavis group hf. - fentanil -
sedaton 100 mikrogramm/h transzdermális tapasz
actavis group hf. - fentanil -